ArticleEuropean radiology2020

Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.

Sébastien Mulé et al.PubMed ↗Publisher ↗

No numbers read from the abstract.